<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20925951</article-id><article-id pub-id-type="pmc">2958944</article-id><article-id pub-id-type="publisher-id">1471-2407-10-533</article-id><article-id pub-id-type="doi">10.1186/1471-2407-10-533</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Randomised phase I/II study to evaluate <italic>c</italic>arbon <italic>i</italic>o<italic>n </italic>ra<italic>d</italic>ioth<italic>e</italic>rapy ve<italic>r</italic>sus fractionat<italic>e</italic>d stereotactic radiotherapy in patients with recurrent or progressive g<italic>l</italic>iom<italic>a</italic>s: The CINDERELLA trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Combs</surname><given-names>Stephanie E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stephanie.combs@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Burkholder</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>StaBiL@Burkholder.de</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Edler</surname><given-names>Lutz</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>l.edler@dkfz.de</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Rieken</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stefan.rieken@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Habermehl</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>daniel.habermehl@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Jäkel</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>oliver.jaekel@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Haberer</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Thomas.haberer@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Haselmann</surname><given-names>Renate</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>renate.haselmann@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Unterberg</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>andreas.unterberg@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Wick</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>wolfgang.wick@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Debus</surname><given-names>Jürgen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>juergen.debus@med.uni-heidelberg.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany</aff><aff id="I2"><label>2</label>Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany</aff><aff id="I3"><label>3</label>Heidelberger Ionenstrahl Therapiezentrum (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany</aff><aff id="I4"><label>4</label>Department of Neurooncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany</aff><aff id="I5"><label>5</label>Department of Neurosurgery, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>6</day><month>10</month><year>2010</year></pub-date><volume>10</volume><fpage>533</fpage><lpage>533</lpage><history><date date-type="received"><day>22</day><month>7</month><year>2010</year></date><date date-type="accepted"><day>6</day><month>10</month><year>2010</year></date></history><permissions><copyright-statement>Copyright ©2010 Combs et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Combs et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/10/533"></self-uri><abstract><sec><title><offsets xml_i="5469" xml_f="5479" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5490" xml_f="6008" txt_i="22" txt_f="540">Treatment of patients with recurrent glioma includes neurosurgical resection, chemotherapy, or radiation therapy. In most cases, a full course of radiotherapy has been applied after primary diagnosis, therefore application of re-irradiation has to be applied cauteously. With modern precision photon techniques such as fractionated stereotactic radiotherapy (FSRT), a second course of radiotherapy is safe and effective and leads to survival times of 22, 16 and 8 months for recurrent WHO grade II, III and IV gliomas.</offsets></p><p><offsets xml_i="6015" xml_f="6508" txt_i="541" txt_f="1034">Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the GBM cell line as well as the endpoint analyzed. Protons, however, offer an RBE which is comparable to photons.</offsets></p><p><offsets xml_i="6515" xml_f="6706" txt_i="1035" txt_f="1226">First Japanese Data on the evaluation of carbon ion radiation therapy for the treatment of primary high-grade gliomas showed promising results in a small and heterogeneous patient collective.</offsets></p></sec><sec><title><offsets xml_i="6728" xml_f="6742" txt_i="1228" txt_f="1242">Methods Design</offsets></title><p><offsets xml_i="6753" xml_f="7289" txt_i="1243" txt_f="1779">In the current Phase I/II-CINDERELLA-trial re-irradiation using carbon ions will be compared to FSRT applied to the area of contrast enhancement representing high-grade tumor areas in patients with recurrent gliomas. Within the Phase I Part of the trial, the Recommended Dose (RD) of carbon ion radiotherapy will be determined in a dose escalation scheme. In the subsequent randomized Phase II part, the RD will be evaluated in the experimental arm, compared to the standard arm, FSRT with a total dose of 36 Gy in single doses of 2 Gy.</offsets></p><p><offsets xml_i="7296" xml_f="7484" txt_i="1780" txt_f="1968">Primary endpoint of the Phase I part is toxicity. Primary endpoint of the randomized part II is survival after re-irradiation at 12 months, secondary endpoint is progression-free survival.</offsets></p></sec><sec><title><offsets xml_i="7506" xml_f="7516" txt_i="1970" txt_f="1980">Discussion</offsets></title><p><offsets xml_i="7527" xml_f="7761" txt_i="1981" txt_f="2215">The Cinderella trial is the first study to evaluate carbon ion radiotherapy for recurrent gliomas, and to compare this treatment to photon FSRT in a randomized setting using an ion beam delivered by intensity modulated rasterscanning.</offsets></p></sec><sec><title><offsets xml_i="7783" xml_f="7801" txt_i="2217" txt_f="2235">Trial Registration</offsets></title><p><offsets xml_i="7812" xml_f="7823" txt_i="2236" txt_f="2247">NCT01166308</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="7885" xml_f="7895" txt_i="2256" txt_f="2266">Background</offsets></title><p><offsets xml_i="7906" xml_f="8263" txt_i="2267" txt_f="2624">Recurrent gliomas remain a major challenge in radiation oncology. In the past, second courses of radiotherapy have only been applied reluctantly, in fear of treatment-related side effects. However, modern radiation techniques have enabled the radiation oncologist to deliver high local doses as an effective salvage treatment with low rates of side effects.</offsets></p><p><offsets xml_i="8270" xml_f="8576" txt_i="2625" txt_f="2931">Especially for GBM, with unsatisfactory outcomes even after extensive research over the past centuries, effective treatment at tumor recurrence are needed urgently. With surgery and supportive care alone, overall survival is about 3-5 months. Postoperative RT can increase overall survival to 9-12 months [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8607" xml_f="8608" txt_i="2931" txt_f="2932">1</offsets></xref><offsets xml_i="8615" xml_f="9328" txt_i="2932" txt_f="3645">]. A number of studies have shown that an additional treatment with chemotherapy can increase overall survival. This benefit, however, is commonly associated with a high risk of treatment-related side effects, especially with combination treatments, such as PCV, and with BCNU. Only recently, significant increase in overall survival could be achieved by adding TMZ, an orally applicable alkylating substance, to postoperative radiotherapy. In a prospective randomized Phase III study performed by the EORTC radiochemotherapy with TMZ was compared to postoperative radiation alone. Overall survival could be increased from 12.1 months to 14.6 months, with acceptable toxicity. TMZ was applied in a dose of 75 mg/m</offsets><sup><offsets xml_i="9333" xml_f="9334" txt_i="3645" txt_f="3646">2</offsets></sup><offsets xml_i="9340" xml_f="9404" txt_i="3646" txt_f="3710">/die during radiotherapy, followed by 6 cycles of adjuvant TMZ [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="9435" xml_f="9436" txt_i="3710" txt_f="3711">2</offsets></xref><offsets xml_i="9443" xml_f="9606" txt_i="3711" txt_f="3874">]. Therefore, standard treatment of patients with GBM is currently considered to be postoperative radiochemotherapy with TMZ, followed by 6 cycles or adjuvant TMZ.</offsets></p><p><offsets xml_i="9613" xml_f="9781" txt_i="3875" txt_f="4043">However, with an overall survival of about 15 months, treatment outcome still remains insufficient, and patients develop tumor recurrences soon after primary diagnosis.</offsets></p><p><offsets xml_i="9788" xml_f="9980" txt_i="4044" txt_f="4236">For anaplastic gliomas, overall survival after standard treatment following primary diagnosis, including neurosurgical resection and postoperative radiotherapy, lies between 18 and 50 months [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="10011" xml_f="10012" txt_i="4236" txt_f="4237">3</offsets></xref><offsets xml_i="10019" xml_f="10148" txt_i="4237" txt_f="4366">]. However, also these patients develop tumor recurrences after primary diagnosis, and effective salvage treatments are required.</offsets></p><p><offsets xml_i="10155" xml_f="10591" txt_i="4367" txt_f="4803">Treatment of low grade gliomas has been discussed controversially over the last years with respect to optimal radiation dose and time point of radiotherapy. It has been shown, that doses of 45-54 Gy are sufficient for long-term local tumor control, and that early application of radiotherapy can increase progression-free survival significantly, without altering overall survival as compared to treatment applied for tumor progression [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="10622" xml_f="10623" txt_i="4803" txt_f="4804">4</offsets></xref><offsets xml_i="10630" xml_f="10750" txt_i="4804" txt_f="4924">]. During follow-up, patients develop not only low grade tumor progression, but also high-grade malignant tumor lesions.</offsets></p><p><offsets xml_i="10757" xml_f="10935" txt_i="4925" txt_f="5103">In the past, a second course of radiotherapy has been applied reluctantly with conventional techniques as treatment outcome outweighs the risk of treatment-related side effects [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="10966" xml_f="10967" txt_i="5103" txt_f="5104">5</offsets></xref><offsets xml_i="10974" xml_f="11190" txt_i="5104" txt_f="5320">]. With modern high-precision stereotactic photon techniques, such as Fractionated Stereotactic Radiotherapy (FSRT) re-irradiation could be established as a safe and effective treatment option for recurrent gliomas [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="11221" xml_f="11222" txt_i="5320" txt_f="5321">6</offsets></xref><offsets xml_i="11229" xml_f="11419" txt_i="5321" txt_f="5511">]. Survival times of 111, 50 and 21 months for WHO Grade II, III and IV gliomas could be shown with FSRT, with very low rates of side effects. However, outcome still remains unsatisfactory [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="11450" xml_f="11451" txt_i="5511" txt_f="5512">7</offsets></xref><offsets xml_i="11458" xml_f="11460" txt_i="5512" txt_f="5514">].</offsets></p><p><offsets xml_i="11467" xml_f="11902" txt_i="5515" txt_f="5950">Charged particles provide the physical advantage of an inverted dose profile which enables steep dose gradients. Neighboring organs at risk and surrounding normal tissue can be spared from radiation doses. Additionally, heavy charged particles, such as carbon ions, as high-LET beams, are characterized by an enhanced RBE. For glioblastoma cell lines, RBE values between 2 and 5 have been reported depending on cell line and endpoint [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="11933" xml_f="11934" txt_i="5950" txt_f="5951">8</offsets></xref><offsets xml_i="11941" xml_f="11942" txt_i="5951" txt_f="5952">,</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="11973" xml_f="11974" txt_i="5952" txt_f="5953">9</offsets></xref><offsets xml_i="11981" xml_f="11983" txt_i="5953" txt_f="5955">].</offsets></p><p><offsets xml_i="11990" xml_f="12253" txt_i="5956" txt_f="6219">In general, GBM are treatment-resistant tumors. Early studies using a high-dose proton boost could show that total doses up to 90 Gy E were effective in preventing local tumor recurrences, however, such high doses were associated with high rates of side effects [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="12285" xml_f="12287" txt_i="6219" txt_f="6221">10</offsets></xref><offsets xml_i="12294" xml_f="12760" txt_i="6221" txt_f="6687">]. Therefore, in general, standard radiation therapy is applied up to a total dose of 60 Gy. Besides the physical advantages of high local dose deposition provided by protons, carbon ions are a promising treatment alternative due to their biological benefits. A clinical study performed by the National Institute of Radiological Sciences (NIRS) treated 48 patients with malignant gliomas with a carbon ion boost up to total doses of 24.8 Gy E, of which 32 were GBM [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="12792" xml_f="12794" txt_i="6687" txt_f="6689">11</offsets></xref><offsets xml_i="12801" xml_f="13059" txt_i="6689" txt_f="6947">]. In this study, no treatment related toxicity exceeding CTCAE Grade II or higher were observed. Therefore, the concept of a carbon ion radiotherapy for the treatment of recurrent gliomas with contrast enhancing lesions is a promising treatment alternative.</offsets></p><p><offsets xml_i="13066" xml_f="13463" txt_i="6948" txt_f="7345">Carbon ion radiotherapy was available by the Department of Radiation Oncology at the Gesellschaft für Schwerionenforschung (GSI) in Darmstadt since 1997. Superior treatment results for a number of tumor entities, such as chordomas and chondrosarcomas of the skull base, as well as ACC have been shown, and carbon ion radiotherapy is currently performed in the clinical routine for these patients [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="13495" xml_f="13497" txt_i="7345" txt_f="7347">12</offsets></xref><offsets xml_i="13504" xml_f="13505" txt_i="7347" txt_f="7348">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="13537" xml_f="13539" txt_i="7348" txt_f="7350">13</offsets></xref><offsets xml_i="13546" xml_f="13831" txt_i="7350" txt_f="7635">]. Safety of carbon ion radiotherapy with respect to critical organs at risk, such as the brain, brainstem or spinal chord, have been shown in these studies. At the Heidelberg Ion Therapy Center (HIT), treatment of over 1300 patients per year with Proton and Carbon ion RT is possible.</offsets></p><p><italic><offsets xml_i="13846" xml_f="13855" txt_i="7636" txt_f="7645">In vitro </offsets></italic><offsets xml_i="13864" xml_f="13964" txt_i="7645" txt_f="7745">data for the treatment of GBM with carbon ions have shown superior effectivity compared to photons [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="13996" xml_f="13998" txt_i="7745" txt_f="7747">14</offsets></xref><offsets xml_i="14005" xml_f="14199" txt_i="7747" txt_f="7941">]. Our own data have shown a high RBE for carbon ion RT for GBM; additionally a combination of carbon ion radiotherapy and TMZ have been evaluated and show an additive effect in GBM-cell lines [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="14230" xml_f="14231" txt_i="7941" txt_f="7942">8</offsets></xref><offsets xml_i="14238" xml_f="14355" txt_i="7942" txt_f="8059">]. A first clinical study evaluating a carbon ion boost in patients with GBM was recently published by Mizoe et al. [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="14387" xml_f="14389" txt_i="8059" txt_f="8061">15</offsets></xref><offsets xml_i="14396" xml_f="14796" txt_i="8061" txt_f="8461">]. Median overall survival in patients with glioblastoma was 17 months; however, only small patient numbers were evaluated and standard chemotherapy with TMZ was not applied. In that study, the carbon ion boost was applied with increasing total doses up to 24.8 Gy E. While toxicity was low even in the high dose arm, the data showed that patients seem to benefit from the high dose carbon ion boost.</offsets></p><p><offsets xml_i="14803" xml_f="15021" txt_i="8462" txt_f="8680">The promising results in primary GBM and the known physical and biological properties of carbon ion offer a promising treatment alternative that should be evaluated for the treatment of patients with recurrent gliomas.</offsets></p><p><offsets xml_i="15028" xml_f="15489" txt_i="8681" txt_f="9142">In the present CINDERELLA trial, the impact of carbon ion radiotherapy using intensity modulated rasterscanning will be compared to FSRT which is considered the treatment standard alternative for patients with recurrent gliomas. In a first Phase I design, the RD of carbon ion radiotherapy for re-irradiation of gliomas will be determined. In the following Phase II part, the RD of carbon ions will be compared to standard photon radiotherapy delivered as FSRT,</offsets></p></sec><sec><title><offsets xml_i="15511" xml_f="15529" txt_i="9144" txt_f="9162">Methods and Design</offsets></title><sec><title><offsets xml_i="15549" xml_f="15561" txt_i="9163" txt_f="9175">Study design</offsets></title><p><offsets xml_i="15572" xml_f="15657" txt_i="9176" txt_f="9261">The trial will be performed as a single-center two-armed randomized Phase I/II study.</offsets></p><sec><title><offsets xml_i="15673" xml_f="15697" txt_i="9262" txt_f="9286">Phase I: Dose Escalation</offsets></title><p><offsets xml_i="15708" xml_f="15895" txt_i="9287" txt_f="9474">Patients fulfilling the inclusion criteria will be treated with increasing total doses of carbon ion radiotherapy to RD of carbon ion radiotherapy for re-irradiation of recurrent gliomas.</offsets></p><p><offsets xml_i="15902" xml_f="16005" txt_i="9475" txt_f="9578">Patients will be treated within seven increasing dose regimens starting at 10 × 3 GyE up to 16 × 3 GyE.</offsets></p></sec><sec><title><offsets xml_i="16027" xml_f="16052" txt_i="9580" txt_f="9605">Phase II: Randomized Part</offsets></title><p><offsets xml_i="16063" xml_f="16139" txt_i="9606" txt_f="9682">Patients fulfilling the inclusion criteria will be randomized into two arms:</offsets></p><p><offsets xml_i="16146" xml_f="16170" txt_i="9683" txt_f="9707">Arm A - Experimental Arm</offsets></p><p><offsets xml_i="16177" xml_f="16205" txt_i="9708" txt_f="9736">Carbon Ion Radiation Therapy</offsets></p><p><offsets xml_i="16212" xml_f="16303" txt_i="9737" txt_f="9828">The total dose applied will be the RD determined in the Phase I part of the study protocol.</offsets></p><p><offsets xml_i="16310" xml_f="16330" txt_i="9829" txt_f="9849">Arm B - Standard Arm</offsets></p><p><offsets xml_i="16337" xml_f="16388" txt_i="9850" txt_f="9901">Fractionated Stereotactic Radiotherapy with Photons</offsets></p><p><offsets xml_i="16395" xml_f="16443" txt_i="9902" txt_f="9950">Total Dose 36 Gy, 18 fractions, 2 Gy single dose</offsets></p><p><offsets xml_i="16450" xml_f="16493" txt_i="9951" txt_f="9994">A flow chart of the study is shown in Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="16523" xml_f="16524" txt_i="9994" txt_f="9995">1</offsets></xref><offsets xml_i="16531" xml_f="16532" txt_i="9995" txt_f="9996">.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="16573" xml_f="16581" txt_i="9997" txt_f="10005">Figure 1</offsets></label><caption><p><bold><offsets xml_i="16607" xml_f="16641" txt_i="10005" txt_f="10039">Flow Chart of the Cinderella-Study</offsets></bold><offsets xml_i="16648" xml_f="16649" txt_i="10039" txt_f="10040">.</offsets></p></caption><graphic xlink:href="1471-2407-10-533-1"></graphic></fig></sec></sec><sec><title><offsets xml_i="16744" xml_f="16760" txt_i="10043" txt_f="10059">Study objectives</offsets></title><p><offsets xml_i="16771" xml_f="16985" txt_i="10060" txt_f="10274">The purpose of the trial is to compare carbon ion radiotherapy to FSRT for the treatment of recurrent gliomas delivered to the area of contrast-enhancement in T1-weighted MRI and/or Amino-Acid-PET-positive lesions.</offsets></p><p><offsets xml_i="16992" xml_f="17129" txt_i="10275" txt_f="10412">In the Phase I study, the RD of carbon ion radiotherapy will be determined in a dose escalation scheme. The primary endpoint is toxicity.</offsets></p><p><offsets xml_i="17136" xml_f="17403" txt_i="10413" txt_f="10680">In the randomized Phase II part of the study, carbon ion radiotherapy treated at the recommended dose evaluated in the phase I part will be compared to standard photon radiotherapy delivered as FSRT. The primary endpoint is survival after re-irradiation at 12 months.</offsets></p></sec><sec><title><offsets xml_i="17425" xml_f="17443" txt_i="10682" txt_f="10700">Primary Objectives</offsets></title><sec><title><offsets xml_i="17463" xml_f="17470" txt_i="10701" txt_f="10708">Phase I</offsets></title><p><offsets xml_i="17481" xml_f="17587" txt_i="10709" txt_f="10815">The primary objective is any Grade IV toxicity related to the study treatment according to CTCAE Grade IV.</offsets></p></sec><sec><title><offsets xml_i="17609" xml_f="17617" txt_i="10817" txt_f="10825">Phase II</offsets></title><p><offsets xml_i="17628" xml_f="17696" txt_i="10826" txt_f="10894">The primary objective is survival after re-irradiation at 12 months.</offsets></p></sec></sec><sec><title><offsets xml_i="17724" xml_f="17744" txt_i="10897" txt_f="10917">Secondary Objectives</offsets></title><sec><title><offsets xml_i="17764" xml_f="17771" txt_i="10918" txt_f="10925">Phase I</offsets></title><p><offsets xml_i="17782" xml_f="17858" txt_i="10926" txt_f="11002">The secondary objective in the Phase I part is survival after re-irradiation</offsets></p></sec><sec><title><offsets xml_i="17880" xml_f="17888" txt_i="11004" txt_f="11012">Phase II</offsets></title><p><offsets xml_i="17899" xml_f="17988" txt_i="11013" txt_f="11102">The secondary objectives of the study are progression-free survival, toxicity and safety.</offsets></p></sec></sec><sec><title><offsets xml_i="18016" xml_f="18053" txt_i="11105" txt_f="11142">Patient selection: Inclusion criteria</offsets></title><p><offsets xml_i="18064" xml_f="18157" txt_i="11143" txt_f="11236">Patients meeting all of the following criteria will be considered for admission to the trial:</offsets></p><p><offsets xml_i="18164" xml_f="18286" txt_i="11237" txt_f="11359">- unifocal, supratentorial recurrent glioma (primary histologies including any WHO Grade II or III glioma or glioblastoma)</offsets></p><p><offsets xml_i="18293" xml_f="18339" txt_i="11360" txt_f="11406">- prior course of standard photon radiotherapy</offsets></p><p><offsets xml_i="18346" xml_f="18441" txt_i="11407" txt_f="11502">- contrast enhancement on T1-weighted MRI and/or Amino-Acid-PET-positive high-grade tumor areas</offsets></p><p><offsets xml_i="18448" xml_f="18475" txt_i="11503" txt_f="11530">- indication re-irradiation</offsets></p><p><offsets xml_i="18482" xml_f="18505" txt_i="11531" txt_f="11554">- age ≥ 18 years of age</offsets></p><p><offsets xml_i="18512" xml_f="18545" txt_i="11555" txt_f="11588">- Karnofsky Performance Score ≥60</offsets></p><p><offsets xml_i="18552" xml_f="18626" txt_i="11589" txt_f="11663">- For women with childbearing potential, (and men) adequate contraception.</offsets></p><p><offsets xml_i="18633" xml_f="18727" txt_i="11664" txt_f="11758">- Ability of subject to understand character and individual consequences of the clinical trial</offsets></p><p><offsets xml_i="18734" xml_f="18810" txt_i="11759" txt_f="11835">- Written informed consent (must be available before enrolment in the trial)</offsets></p></sec><sec><title><offsets xml_i="18832" xml_f="18869" txt_i="11837" txt_f="11874">Patient selection: Exclusion criteria</offsets></title><p><offsets xml_i="18880" xml_f="18969" txt_i="11875" txt_f="11964">Patients presenting with any of the following criteria will not be included in the trial:</offsets></p><p><offsets xml_i="18976" xml_f="19018" txt_i="11965" txt_f="12007">- Multifocal Glioma or Gliomatosis cerebri</offsets></p><p><offsets xml_i="19025" xml_f="19076" txt_i="12008" txt_f="12059">- refusal of the patients to take part in the study</offsets></p><p><offsets xml_i="19083" xml_f="19185" txt_i="12060" txt_f="12162">- previous re-irradiation or prior radiosurgery or prior treatment with interstitial radioactive seeds</offsets></p><p><offsets xml_i="19192" xml_f="19251" txt_i="12163" txt_f="12219">- time interval of &lt; 6 months after primary radiotherapy</offsets></p><p><offsets xml_i="19258" xml_f="19336" txt_i="12220" txt_f="12298">- Patients who have not yet recovered from acute toxicities of prior therapies</offsets></p><p><offsets xml_i="19343" xml_f="19541" txt_i="12299" txt_f="12494">- Known carcinoma &lt; 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy</offsets></p><p><offsets xml_i="19548" xml_f="19577" txt_i="12495" txt_f="12524">- Pregnant or lactating women</offsets></p><p><offsets xml_i="19584" xml_f="19682" txt_i="12525" txt_f="12623">- Participation in another clinical study or observation period of competing trials, respectively.</offsets></p></sec><sec><title><offsets xml_i="19704" xml_f="19724" txt_i="12625" txt_f="12645">Treatment Assignment</offsets></title><p><offsets xml_i="19735" xml_f="19912" txt_i="12646" txt_f="12823">Radiation therapy according to the protocol will be performed in patients included into the study and after assignment of the patients to the treatment arms after randomization.</offsets></p><p><offsets xml_i="19919" xml_f="20097" txt_i="12824" txt_f="13002">Patients withdrawn from the trial retain their identification codes (e.g. randomization number, if already given). New patients must always be allotted a new identification code.</offsets></p></sec><sec><title><offsets xml_i="20119" xml_f="20137" txt_i="13004" txt_f="13022">Treatment Planning</offsets></title><p><offsets xml_i="20148" xml_f="20369" txt_i="13023" txt_f="13244">For FSRT and particle therapy, patients will be immobilized using an individually manufactured head mask. For treatment planning, contrast-enhanced CT as well as MR-imaging will be performed for optimal target definition.</offsets></p><p><offsets xml_i="20376" xml_f="20491" txt_i="13245" txt_f="13360">Treatment planning for carbon ion and FSRT is to be performed about 1-2 weeks prior to the start of re-irradiation.</offsets></p><p><offsets xml_i="20498" xml_f="20673" txt_i="13361" txt_f="13536">Organs at risk such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="20705" xml_f="20707" txt_i="13536" txt_f="13538">16</offsets></xref><offsets xml_i="20714" xml_f="20716" txt_i="13538" txt_f="13540">].</offsets></p><p><offsets xml_i="20723" xml_f="20872" txt_i="13541" txt_f="13690">The Treatment Volume for Re-Irradiation will be defined as the area of contrast enhancement on T1-weighted MR-imaging adding a safety margin of 5 mm.</offsets></p><p><offsets xml_i="20879" xml_f="21016" txt_i="13691" txt_f="13828">Amino-Acid-PET or SPECT-Examinations may be used in addition to contrast-enhanced MRI for target volume definition but are not mandatory.</offsets></p><p><offsets xml_i="21023" xml_f="21132" txt_i="13829" txt_f="13938">FSRT planning is performed using standard photon-treatment planning systems such as HELAX, Masterplan or STP.</offsets></p><p><offsets xml_i="21139" xml_f="21440" txt_i="13939" txt_f="14240">Carbon ion RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/β ratio for gliomas as well as for the endpoint late toxicity to the brain.</offsets></p><p><offsets xml_i="21447" xml_f="21545" txt_i="14241" txt_f="14336">No interruptions &gt; 4 days during study treatment (carbon ion radiotherapy or FSRT) are allowed.</offsets></p><p><offsets xml_i="21552" xml_f="21724" txt_i="14337" txt_f="14506">Patient positioning prior to FSRT or particle therapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations &gt;3 mm are corrected prior to radiotherapy.</offsets></p></sec><sec><title><offsets xml_i="21746" xml_f="21789" txt_i="14508" txt_f="14551">Dose Prescription Experimental (Carbon) Arm</offsets></title><p><offsets xml_i="21800" xml_f="22128" txt_i="14552" txt_f="14880">The intensity-controlled rasterscan system will be used for beam application. In the Phase I Dose Escalation Part, increasing doses of carbon ion radiotherapy will be evaluated in 7 steps starting at 10 × 3 Gy E up to 16 × 3 Gy E. In this part, the RD of carbon ion radiotherapy for re-irradiation of gliomas will be determined.</offsets></p><p><offsets xml_i="22135" xml_f="22419" txt_i="14881" txt_f="15165">Therafter, the RD determined will be chosen for the randomized phase II part of the study. The total dose will be prescribed to the maximum of the calculated dose distribution for the target volume. Treatment planning aims in the coverage of the target volume by the 90%-isodose line.</offsets></p><p><offsets xml_i="22426" xml_f="22857" txt_i="15166" txt_f="15597">Dose specification is based on biologic equivalent dose because of the high RBE of carbon ions, which differs throughout the target volume due to its dependence on various factors. RBE will be calculated at each voxel throughout the target volumes and biological optimization will be performed. The dose prescription used is related to the isoeffective dose GyE using daily fractions of 2 Gy and a weekly fractionation of 5 × 3 Gy.</offsets></p><p><offsets xml_i="22864" xml_f="22906" txt_i="15598" txt_f="15640">A typical treatment plan is shown in Fig. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="22936" xml_f="22937" txt_i="15640" txt_f="15641">2</offsets></xref><offsets xml_i="22944" xml_f="22945" txt_i="15641" txt_f="15642">.</offsets></p><fig id="F2" position="float"><label><offsets xml_i="22986" xml_f="22994" txt_i="15643" txt_f="15651">Figure 2</offsets></label><caption><p><bold><offsets xml_i="23020" xml_f="23114" txt_i="15651" txt_f="15745">Typical treatment plan for carbon ion radiotherapy for a patients with a recurrent glioblatoma</offsets></bold><offsets xml_i="23121" xml_f="23273" txt_i="15745" txt_f="15897">. Treatment is performed using the Siemens TPS for particle therapy, target volume delienation is based on CT- and MR-imaging with contrast enhancement.</offsets></p></caption><graphic xlink:href="1471-2407-10-533-2"></graphic></fig></sec><sec><title><offsets xml_i="23362" xml_f="23401" txt_i="15899" txt_f="15938">Dose Prescription Standard (Photon) Arm</offsets></title><p><offsets xml_i="23412" xml_f="23606" txt_i="15939" txt_f="16133">Eighteen fractions of a single dose of 2 Gy up to a total dose of 36 Gy will be prescribed to the isocenter. Treatment planning aims in the coverage of the target volume by the 90%-isodose line.</offsets></p></sec><sec><title><offsets xml_i="23628" xml_f="23674" txt_i="16135" txt_f="16181">Statistical calculations for trial sample size</offsets></title><p><offsets xml_i="23685" xml_f="23833" txt_i="16182" txt_f="16330">The statistical methods applied for this study are subject to GCP guidelines (Guidelines of the International Conference on Harmonisation (ICH) e.g.</offsets></p><p><offsets xml_i="23840" xml_f="23899" txt_i="16331" txt_f="16390">• ICH E3: Structure and Contents of Clinical Study Reports,</offsets></p><p><offsets xml_i="23906" xml_f="23969" txt_i="16391" txt_f="16454">• ICH E6: Good Clinical Practice (GCP). Consolidated Guideline,</offsets></p><p><offsets xml_i="23976" xml_f="24202" txt_i="16455" txt_f="16681">• ICH E9: Note for Guidance on Statistical Principles in Clinical Trials) and will be performed in accordance with CESAR SOP 8 (Statistical Analysis/Biometry) in their versions valid at the date of the original study protocol.</offsets></p></sec><sec><title><offsets xml_i="24224" xml_f="24240" txt_i="16683" txt_f="16699">Study Hypothesis</offsets></title><sec><title><offsets xml_i="24260" xml_f="24267" txt_i="16700" txt_f="16707">Phase I</offsets></title><p><offsets xml_i="24278" xml_f="24465" txt_i="16708" txt_f="16895">Phase I part of this study is conducted to choose the Recommended Dose (RD) of carbon ion radiotherapy for the phase II part between seven dose levels based on the dose escalation scheme.</offsets></p></sec><sec><title><offsets xml_i="24487" xml_f="24495" txt_i="16897" txt_f="16905">Phase II</offsets></title><p><offsets xml_i="24506" xml_f="24930" txt_i="16906" txt_f="17330">The phase II part of this study is designed to demonstrate superiority in survival of carbon ion radiotherapy (experimental) to FSRT (standard) in patients with recurrent or progressive gliomas. The primary endpoints variable is overall survival time after at least 12 months of follow-up (OS_12m) defined as time to death for any reason during the follow-up period of at least 12 months starting from date of randomization.</offsets></p></sec></sec><sec><title><offsets xml_i="24958" xml_f="24981" txt_i="17333" txt_f="17356">Sample Size Calculation</offsets></title><sec><title><offsets xml_i="25001" xml_f="25008" txt_i="17357" txt_f="17364">Phase I</offsets></title><p><offsets xml_i="25019" xml_f="25313" txt_i="17365" txt_f="17659">Seven DLs are included in the dose finding part. It is assumed that the probability of a DLT is 1/3. With n = 8 patients in each DL, the power that at each DL at least one DLT is observed is greater than 95%. Therefore a maximum of 56 patients will be treated in the phase I part of this study.</offsets></p><p><offsets xml_i="25320" xml_f="25442" txt_i="17660" txt_f="17782">Within this study, DLTs are defined as any grade IV toxicity according to CTCAE Version 4.0 associated to study treatment.</offsets></p></sec><sec><title><offsets xml_i="25464" xml_f="25472" txt_i="17784" txt_f="17792">Phase II</offsets></title><p><offsets xml_i="25483" xml_f="25678" txt_i="17793" txt_f="17988">• The size of the phase II part of this study is determined by the primary aim of testing experimental treatment for superiority over standard treatment. This endpoint is a censored failure time.</offsets></p><p><offsets xml_i="25685" xml_f="25708" txt_i="17989" txt_f="18012">• Information on the OS</offsets><sub><offsets xml_i="25713" xml_f="25714" txt_i="18012" txt_f="18013">B</offsets></sub><offsets xml_i="25720" xml_f="25831" txt_i="18013" txt_f="18124">_12mR (overall survival rate after 12 months of follow-up for standard treatment) is given in literature data [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="25863" xml_f="25865" txt_i="18124" txt_f="18126">17</offsets></xref><offsets xml_i="25872" xml_f="25874" txt_i="18126" txt_f="18128">].</offsets></p><p><offsets xml_i="25881" xml_f="26019" txt_i="18129" txt_f="18267">To calculate survival data, a population distribution of GBM in 34.3%, Grade III Tumors in 24.4% and low grade gliomas in 41.3% was used [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="26051" xml_f="26053" txt_i="18267" txt_f="18269">17</offsets></xref><offsets xml_i="26060" xml_f="26244" txt_i="18269" txt_f="18453">]. Survival rates for overall survival were taken as published previously with 23% for GBM 65% for Grade III, and 77% for low-grade gliomas observed at 12 months after re-irradiation [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="26276" xml_f="26278" txt_i="18453" txt_f="18455">17</offsets></xref><offsets xml_i="26285" xml_f="26287" txt_i="18455" txt_f="18457">].</offsets></p><p><offsets xml_i="26294" xml_f="26304" txt_i="18458" txt_f="18468">Overall OS</offsets><sub><offsets xml_i="26309" xml_f="26310" txt_i="18468" txt_f="18469">B</offsets></sub><offsets xml_i="26316" xml_f="26375" txt_i="18469" txt_f="18528">_12mR can be calculated as weighted mean rate. Therefore OS</offsets><sub><offsets xml_i="26380" xml_f="26381" txt_i="18528" txt_f="18529">B</offsets></sub><offsets xml_i="26387" xml_f="26489" txt_i="18529" txt_f="18631">_12mR is expected to be 56%. The study will be designed to detect an improvement in OS_12mR of 10% (OS</offsets><sub><offsets xml_i="26494" xml_f="26495" txt_i="18631" txt_f="18632">A</offsets></sub><offsets xml_i="26501" xml_f="26514" txt_i="18632" txt_f="18645">_12mR = 66%).</offsets></p><p><offsets xml_i="26521" xml_f="26821" txt_i="18646" txt_f="18946">The statistical error rates for this test of superiority are set as α = 0.05 and β = 0.20 (power 80%). Sample size calculation is based on an unstratified log-rank. It can be expected that including histology in a stratified log-rank test will increase the power as compared to the unstratified test.</offsets></p><p><offsets xml_i="26828" xml_f="27037" txt_i="18947" txt_f="19156">The recruitment period will be 36 months with a minimal follow-up time of 12 months. In order to put more patients on the experimental treatment, an unbalanced randomization allocation ratio of 2:3 was chosen.</offsets></p><p><offsets xml_i="27044" xml_f="27432" txt_i="19157" txt_f="19545">For this set of assumptions, the sample size calculation programme PASS 2008 yields the total sample size for standard treatment of n = 138 and n = 207 for experimental treatment. Allowing for failures for various reasons of 10%, a total of N = 380 is required for this part of the study (n = 152 in standard arm and n = 228 in experimental arm). Patients will be stratified by histology.</offsets></p></sec></sec><sec><title><offsets xml_i="27460" xml_f="27479" txt_i="19548" txt_f="19567">Statistical Methods</offsets></title><sec><title><offsets xml_i="27499" xml_f="27506" txt_i="19568" txt_f="19575">Phase I</offsets></title><sec><title><offsets xml_i="27526" xml_f="27542" txt_i="19576" txt_f="19592">Primary endpoint</offsets></title><p><offsets xml_i="27553" xml_f="27878" txt_i="19593" txt_f="19918">Safety will be assessed by the type, incidence and severity (graded by the NCI CTC-AE Version 4.0) and relation to treatment. All patients treated at least once with one of the seven dose levels defined above will be described individually and summarized by dose level. No confirmatory statistical analysis will be performed.</offsets></p></sec></sec></sec><sec><title><offsets xml_i="27912" xml_f="27930" txt_i="19922" txt_f="19940">Secondary endpoint</offsets></title><p><offsets xml_i="27941" xml_f="28146" txt_i="19941" txt_f="20146">Descriptive summary tables will be presented on baseline patient characteristics as well as for all safety parameters by dose level. Patients will be monitored for adverse events using NCI-CTC version 4.0.</offsets></p><sec><title><offsets xml_i="28162" xml_f="28170" txt_i="20147" txt_f="20155">Phase II</offsets></title><sec><title><offsets xml_i="28190" xml_f="28206" txt_i="20156" txt_f="20172">Primary endpoint</offsets></title><p><offsets xml_i="28217" xml_f="28346" txt_i="20173" txt_f="20302">The primary endpoint variable OS_12 m was planned to be analysed by a one sided logrank test of stratified by histology testing H</offsets><sub><offsets xml_i="28351" xml_f="28352" txt_i="20302" txt_f="20303">0</offsets></sub><offsets xml_i="28358" xml_f="28362" txt_i="20303" txt_f="20307">: OS</offsets><sub><offsets xml_i="28367" xml_f="28368" txt_i="20307" txt_f="20308">A</offsets></sub><offsets xml_i="28374" xml_f="28384" txt_i="20308" txt_f="20318">-12 m = OS</offsets><sub><offsets xml_i="28389" xml_f="28390" txt_i="20318" txt_f="20319">B</offsets></sub><offsets xml_i="28396" xml_f="28410" txt_i="20319" txt_f="20333">-12 m versus H</offsets><sub><offsets xml_i="28415" xml_f="28416" txt_i="20333" txt_f="20334">1</offsets></sub><offsets xml_i="28422" xml_f="28426" txt_i="20334" txt_f="20338">: OS</offsets><sub><offsets xml_i="28431" xml_f="28432" txt_i="20338" txt_f="20339">A</offsets></sub><offsets xml_i="28438" xml_f="28451" txt_i="20339" txt_f="20349">-12 m &gt; OS</offsets><sub><offsets xml_i="28456" xml_f="28457" txt_i="20349" txt_f="20350">B</offsets></sub><offsets xml_i="28463" xml_f="28765" txt_i="20350" txt_f="20652">-12 m at the level of alpha = 5%. One interim analysis is planned when 50% of the number of expected events under the null-hypothesis have occurred. In order to preserve the significance level of 5% a sequential plan with alpha-spending of De-Mets and Lan with limits of O'Brien and Fleming is applied.</offsets></p><p><offsets xml_i="28772" xml_f="29023" txt_i="20653" txt_f="20904">Overall survival will be summarized by Kaplan-Meier curves. Median estimates as well as associated 95% confidence intervals will be reported. Further, a descriptive analysis of the primary outcome variable is performed applying a Cox-regression model.</offsets></p></sec></sec></sec><sec><title><offsets xml_i="29057" xml_f="29076" txt_i="20908" txt_f="20927">Secondary endpoints</offsets></title><p><offsets xml_i="29087" xml_f="29267" txt_i="20928" txt_f="21108">• Progression-free survival will be analyzed analogously to the primary endpoints. P-value of the logrank test and test within the Cox regression will be interpreted descriptively.</offsets></p><p><offsets xml_i="29274" xml_f="29276" txt_i="21109" txt_f="21111">• </offsets><underline><offsets xml_i="29287" xml_f="29302" txt_i="21111" txt_f="21126">Safety/Toxicity</offsets></underline><offsets xml_i="29314" xml_f="29707" txt_i="21126" txt_f="21519"> will be assessed by the type, incidence, severity (graded by the NCT CTCAE Version 4.0), and relatedness of AEs to treatment and by assessment of laboratory parameters related to safety. Tolerability and dosing will be described by numbers of patients in whom treatment was given as planned, delayed or permanently stopped. All analyses will be performed separately for both treatment groups.</offsets></p><p><offsets xml_i="29714" xml_f="29962" txt_i="21520" txt_f="21768">A detailed SAP will be designed after initiating the study and before start of data analysis by the biometric center. It will consider all analyses necessary to characterize the study populations and to evaluate the primary and secondary endpoints.</offsets></p></sec><sec><title><offsets xml_i="29984" xml_f="30000" txt_i="21770" txt_f="21786">Interim Analysis</offsets></title><sec><title><offsets xml_i="30020" xml_f="30027" txt_i="21787" txt_f="21794">Phase I</offsets></title><p><offsets xml_i="30038" xml_f="30138" txt_i="21795" txt_f="21895">Besides the planned analysis during and after phase I part, no further interim analysis are planned.</offsets></p></sec><sec><title><offsets xml_i="30160" xml_f="30168" txt_i="21897" txt_f="21905">Phase II</offsets></title><p><offsets xml_i="30179" xml_f="30492" txt_i="21906" txt_f="22219">For the primary aim and the primary endpoint of the phase II, one interim analysis will be performed when 40% of the expected events under the null-hypothesis have occurred. Under the study hypotheses, 114 events will be occurred under the null hypothesis approximately after 26 months after start of recruitment.</offsets></p><p><offsets xml_i="30499" xml_f="31054" txt_i="22220" txt_f="22775">Using O'Brien-Fleming approach with one scheduled interim analysis, hypothesis testing would be conducted at an interim significance level of α = 0.008. If significance is found in favour of the test treatment, the study may be stopped with sufficient statistical evidence of efficacy. If the level of significance is not reached at the interim analysis, the study continues to normal completion at which time the hypothesis testing is conducted at a significance level of α = 0.042. This stagewise procedure will have an overall significance of α = 0.05.</offsets></p><p><offsets xml_i="31061" xml_f="31171" txt_i="22776" txt_f="22886">If for any reason no confirmative interim analysis will be performed, the final significance level will be 5%.</offsets></p></sec></sec><sec><title><offsets xml_i="31199" xml_f="31221" txt_i="22889" txt_f="22911">Dose Escalation Scheme</offsets></title><p><offsets xml_i="31232" xml_f="31582" txt_i="22912" txt_f="23262">The dose-escalation part of this study was designed to enroll successive cohorts of 8 patients, each to be started on a fixed dose of carbon ion therapy. The starting dose was specified as 10 × 3 Gy E for the first cohort. Planned dose level for subsequent cohorts were 11 × 3 Gy E, 12 × 3 Gy E, 13 × 3 Gy E, 14 × 3 Gy E, 15 × 3 Gy E and 16 × 3 Gy E.</offsets></p><p><offsets xml_i="31589" xml_f="32095" txt_i="23263" txt_f="23769">Dose escalation was to be stopped when the maximum tolerated dose (MTD) was reached. MTD was defined as one dose level below that at which dose limiting toxicities (DLT) was observed in one-third or more of the patients meaning that at least 3 of the 8 patients in one dose cohort experienced a DLT. If maximum 2 DLTs were observed at one dose level, the next higher dose level will be evaluated. The maximum tolerated dose corresponds to the recommended dose for the following phase II part of this trial.</offsets></p><p><offsets xml_i="32102" xml_f="32250" txt_i="23770" txt_f="23918">Toxicities were graded using the NCI Common Toxicity Criteria Version 4.0. DLT was defined as any treatment-related event qualifying as NCI grade 4.</offsets></p></sec><sec><title><offsets xml_i="32272" xml_f="32307" txt_i="23920" txt_f="23955">Ethics, informed consent and safety</offsets></title><p></p><p><offsets xml_i="32325" xml_f="32422" txt_i="23957" txt_f="24054">Before study recruitment, a positive vote of the Bundesamt für Strahlenschutz (BfS) is necessary.</offsets></p></sec><sec><title><offsets xml_i="32444" xml_f="32474" txt_i="24056" txt_f="24086">Treatment at tumor progression</offsets></title><p><offsets xml_i="32485" xml_f="32640" txt_i="24087" txt_f="24242">After completion of study treatment not adjuvant treatment is conducted as part of this protocol. Further treatments may be initiated as needed clinically.</offsets></p><p><offsets xml_i="32647" xml_f="32894" txt_i="24243" txt_f="24490">For tumor progression, treatment alternatives will be evaluated and discussed in the interdisciplinary setting considering options of neurosurgical resection, systemic treatment such as chemotherapy, a second course of radiation therapy, or other.</offsets></p></sec></sec><sec><title><offsets xml_i="32922" xml_f="32932" txt_i="24493" txt_f="24503">Discussion</offsets></title><p><offsets xml_i="32943" xml_f="33468" txt_i="24504" txt_f="25029">Treatment of recurrent gliomas still remains an interdisciplinary challenge. Re-irradiation using high-precision photon techniques has been established as a standard treatment in this clinical situation for a subgroup of patients: Several different fractionation schemes are applied in this setting, including hypofractionated regimens or radiosurgery, however, in our institution, Fractionated Stereotactic Radiotherapy (FSRT) with an attempted total dose of 36 Gy in 2 Gy single fractions is considered standard treatment [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="33500" xml_f="33502" txt_i="25029" txt_f="25031">18</offsets></xref><offsets xml_i="33509" xml_f="33510" txt_i="25031" txt_f="25032">-</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="33542" xml_f="33544" txt_i="25032" txt_f="25034">23</offsets></xref><offsets xml_i="33551" xml_f="33650" txt_i="25034" txt_f="25133">]. Still outcome of these patients is not satisfactory and novel treatment appraoches are required.</offsets></p><p><offsets xml_i="33657" xml_f="33987" txt_i="25134" txt_f="25464">With heavy charged particle beams such as carbon ions, the physical benefits of an ion beam in conjunction with the higher relative biological effectiveness (RBE) can be exploited for the treatment of different tumor entities. For several indications, superior clinical results as compared to photon radiotherapy have been shown [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="34019" xml_f="34021" txt_i="25464" txt_f="25466">24</offsets></xref><offsets xml_i="34028" xml_f="34232" txt_i="25466" txt_f="25670">]. Preclinical studies have shown the RBE to be between 3 and 5 for high-grade gliomas, therefore demonstrating that carbon ions are a promising treatment alternative for patients with recurrent gliomas [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="34263" xml_f="34264" txt_i="25670" txt_f="25671">8</offsets></xref><offsets xml_i="34271" xml_f="34272" txt_i="25671" txt_f="25672">,</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="34304" xml_f="34306" txt_i="25672" txt_f="25674">25</offsets></xref><offsets xml_i="34313" xml_f="34315" txt_i="25674" txt_f="25676">].</offsets></p><p><offsets xml_i="34322" xml_f="34618" txt_i="25677" txt_f="25973">Early clincial data on carbon ion radiotherapy in primary high-grade brain tumors have shown overall safety even with extensive dose escalation with promising results; however, few patients had been included into this study, and therefore validation in a larger patients collective is warranted [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="34650" xml_f="34652" txt_i="25973" txt_f="25975">26</offsets></xref><offsets xml_i="34659" xml_f="34661" txt_i="25975" txt_f="25977">].</offsets></p><p><offsets xml_i="34668" xml_f="34867" txt_i="25978" txt_f="26177">Until now, no patients have been treated with carbon ion radiotherapy for recurrent gliomas. Based on the preclinical data as well as the clinical experience so far, this concept should be evaluated.</offsets></p><p><offsets xml_i="34874" xml_f="35346" txt_i="26178" txt_f="26650">Therefore, the present CINDERELLA trial evaluates carbon ion radiotherapy performed as re-irradiation in patients with recurrent gliomas compared to FSRT with standard dosing. In a first Phase I part of the study, a dose escalation will be performed to determine the optimal dose of carbon ion radiotherapy that can be prescribed in this clinical setting. Thereafter, in the Phase II part of the trial, patients will be randomized between carbon ion radiotherapy and FSRT.</offsets></p></sec><sec><title><offsets xml_i="35368" xml_f="35381" txt_i="26652" txt_f="26665">Abbreviations</offsets></title><p><offsets xml_i="35392" xml_f="35846" txt_i="26666" txt_f="27120">ACC: Adenoid Cystic Carcinomas; BCNU: Carmustine; DL: Dose level; DLT: Dose limiting toxicity; FSRT: Fractionated Stereotactic Radiotherapy; GBM: Glioblastoma; GSI: Gesellschaft für Schwerionenforschung; GY E: Gray Equivalent; HIT: Heidelberger Ionenstrahl herapiezentrum; NIRS: National Institute for Radiological Sciences; RBE: Relative Biological Effectiveness; RD: Recommended Dose; RT: Radiotherapy; TMZ: Temozolomide; WHO: World Health Organization</offsets></p></sec><sec><title><offsets xml_i="35868" xml_f="35887" txt_i="27122" txt_f="27141">Competing interests</offsets></title><p><offsets xml_i="35898" xml_f="35956" txt_i="27142" txt_f="27200">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="35978" xml_f="36000" txt_i="27202" txt_f="27224">Authors' contributions</offsets></title><p><offsets xml_i="36011" xml_f="36428" txt_i="27225" txt_f="27642">SEC, JD, IB, LE and WW have developed the study concept. SEC, JD, IB and LE wrote the study protocol and obtained ethics approval. SEC, JD, WW, AU, SR and DH will provide patient care. TH and OJ will perform treatment planning and beam application for carbon ion radiotherapy. SEC, WW and JD will implement the protocol and oversee collection of the data. All authors contributed to and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="36450" xml_f="36473" txt_i="27644" txt_f="27667">Pre-publication history</offsets></title><p><offsets xml_i="36484" xml_f="36548" txt_i="27668" txt_f="27732">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/10/533/prepub"><offsets xml_i="36651" xml_f="36703" txt_i="27733" txt_f="27785">http://www.biomedcentral.com/1471-2407/10/533/prepub</offsets></ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>The research defining the role of carbon ion radiotherapy for primary brain tumors and tumors of the skull base is financed within the Klinische Forschergruppe „Schwerionentherapie in der Radioonkologie" KFO 214 supoerted by the Deutsche Forschungsgemeinschaft (DFG).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>MD</given-names></name><name><surname>Strike</surname><given-names>TA</given-names></name><name><surname>Sheline</surname><given-names>GE</given-names></name><article-title>An analysis of dose-effect relationship in the radiotherapy of malignant gliomas</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1979</year><volume>5</volume><fpage>1725</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">231022</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><etal></etal><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>987</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043330</pub-id><pub-id pub-id-type="pmid">15758009</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Nagy</surname><given-names>M</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><name><surname>Bischof</surname><given-names>M</given-names></name><name><surname>Welzel</surname><given-names>T</given-names></name><name><surname>Hof</surname><given-names>H</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><etal></etal><article-title>Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas</article-title><source>Tumori</source><year>2009</year><volume>95</volume><fpage>317</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19688970</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Afra</surname><given-names>D</given-names></name><name><surname>de Witte</surname><given-names>O</given-names></name><name><surname>Ben Hassel</surname><given-names>M</given-names></name><name><surname>Schraub</surname><given-names>S</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K</given-names></name><etal></etal><article-title>Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>985</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67070-5</pub-id><pub-id pub-id-type="pmid">16168780</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Bauman</surname><given-names>GS</given-names></name><name><surname>Sneed</surname><given-names>PK</given-names></name><name><surname>Wara</surname><given-names>WM</given-names></name><name><surname>Stalpers</surname><given-names>LJ</given-names></name><name><surname>Chang</surname><given-names>SM</given-names></name><name><surname>McDermott</surname><given-names>MW</given-names></name><etal></etal><article-title>Reirradiation of primary CNS tumors</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1996</year><volume>36</volume><fpage>433</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">8892469</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Edler</surname><given-names>L</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><article-title>Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>8863</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.03.4157</pub-id><pub-id pub-id-type="pmid">16314646</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Edler</surname><given-names>L</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><article-title>Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>8863</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.03.4157</pub-id><pub-id pub-id-type="pmid">16314646</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="other"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Bohl</surname><given-names>J</given-names></name><name><surname>Elsaesser</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>KJ</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><etal></etal><article-title>Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines</article-title><source>Int J Rad Biol</source><year>2008</year><comment> in press </comment></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Iwadate</surname><given-names>Y</given-names></name><name><surname>Mizoe</surname><given-names>J</given-names></name><name><surname>Osaka</surname><given-names>Y</given-names></name><name><surname>Yamaura</surname><given-names>A</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><article-title>High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2001</year><volume>50</volume><fpage>803</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11395250</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Fitzek</surname><given-names>MM</given-names></name><name><surname>Thornton</surname><given-names>AF</given-names></name><name><surname>Rabinov</surname><given-names>JD</given-names></name><name><surname>Lev</surname><given-names>MH</given-names></name><name><surname>Pardo</surname><given-names>FS</given-names></name><name><surname>Munzenrider</surname><given-names>JE</given-names></name><etal></etal><article-title>Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial</article-title><source>J Neurosurg</source><year>1999</year><volume>91</volume><fpage>251</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.3171/jns.1999.91.2.0251</pub-id><pub-id pub-id-type="pmid">10433313</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Mizoe</surname><given-names>JE</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>A</given-names></name><name><surname>Yanagi</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>R</given-names></name><name><surname>Kamada</surname><given-names>T</given-names></name><etal></etal><article-title>Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>69</volume><fpage>390</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17459607</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><name><surname>Karger</surname><given-names>CP</given-names></name><name><surname>Feuerhake</surname><given-names>A</given-names></name><name><surname>Nikoghosyan</surname><given-names>A</given-names></name><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Jakel</surname><given-names>O</given-names></name><etal></etal><article-title>Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>68</volume><fpage>449</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">17363188</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><name><surname>Nikoghosyan</surname><given-names>A</given-names></name><name><surname>Hof</surname><given-names>H</given-names></name><name><surname>Didinger</surname><given-names>B</given-names></name><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Jakel</surname><given-names>O</given-names></name><etal></etal><article-title>Carbon ion radiotherapy of skull base chondrosarcomas</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>67</volume><fpage>171</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17056193</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Iwadate</surname><given-names>Y</given-names></name><name><surname>Mizoe</surname><given-names>J</given-names></name><name><surname>Osaka</surname><given-names>Y</given-names></name><name><surname>Yamaura</surname><given-names>A</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><article-title>High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2001</year><volume>50</volume><fpage>803</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11395250</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Mizoe</surname><given-names>JE</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>A</given-names></name><name><surname>Yanagi</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>R</given-names></name><name><surname>Kamada</surname><given-names>T</given-names></name><etal></etal><article-title>Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>69</volume><fpage>390</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17459607</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Emami</surname><given-names>B</given-names></name><name><surname>Lyman</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Coia</surname><given-names>L</given-names></name><name><surname>Goitein</surname><given-names>M</given-names></name><name><surname>Munzenrider</surname><given-names>JE</given-names></name><etal></etal><article-title>Tolerance of normal tissue to therapeutic irradiation</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1991</year><volume>21</volume><fpage>109</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">2032882</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Edler</surname><given-names>L</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>DL</given-names></name><article-title>Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>8863</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.03.4157</pub-id><pub-id pub-id-type="pmid">16314646</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Gutwein</surname><given-names>S</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><article-title>Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT)</article-title><source>Strahlenther Onkol</source><year>2005</year><volume>181</volume><fpage>768</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s00066-005-1415-6</pub-id><pub-id pub-id-type="pmid">16362786</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Edler</surname><given-names>L</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><article-title>Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>8863</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.03.4157</pub-id><pub-id pub-id-type="pmid">16314646</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Widmer</surname><given-names>V</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Hof</surname><given-names>H</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><article-title>Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM)</article-title><source>Cancer</source><year>2005</year><volume>104</volume><fpage>2168</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/cncr.21429</pub-id><pub-id pub-id-type="pmid">16220556</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Gutwein</surname><given-names>S</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Huber</surname><given-names>P</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><article-title>Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme</article-title><source>J Neurooncol</source><year>2005</year><volume>74</volume><fpage>167</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s11060-004-2463-y</pub-id><pub-id pub-id-type="pmid">16193388</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Ahmadi</surname><given-names>R</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><name><surname>Thilmann</surname><given-names>C</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><article-title>Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation</article-title><source>J Neurooncol</source><year>2005</year><volume>71</volume><fpage>319</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s11060-004-2029-z</pub-id><pub-id pub-id-type="pmid">15735924</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Combs</surname><given-names>SE</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><article-title>Radiotherapeutic alternatives for previously irradiated recurrent gliomas</article-title><source>BMC Cancer</source><year>2007</year><volume>7</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-7-167</pub-id><pub-id pub-id-type="pmid">17760992</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Schulz-Ertner</surname><given-names>D</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><article-title>Particle radiation therapy using proton and heavier ion beams</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>953</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.7816</pub-id><pub-id pub-id-type="pmid">17350944</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Iwadate</surname><given-names>Y</given-names></name><name><surname>Mizoe</surname><given-names>J</given-names></name><name><surname>Osaka</surname><given-names>Y</given-names></name><name><surname>Yamaura</surname><given-names>A</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><article-title>High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2001</year><volume>50</volume><fpage>803</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11395250</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Mizoe</surname><given-names>JE</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>A</given-names></name><name><surname>Yanagi</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>R</given-names></name><name><surname>Kamada</surname><given-names>T</given-names></name><etal></etal><article-title>Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>69</volume><fpage>390</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17459607</pub-id></mixed-citation></ref></ref-list></back></article>